John Kuruvilla

Also affiliated with Princess Margaret Cancer Centre

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: “Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up”.

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up

Blood Advances(2023)10.1182/bloodadvances.2023010254

N/A

0.960DataRank · unranked

38 citations

Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla +9 more

Blood-based biomarkers of cancer-related cognitive impairment in non-central nervous system cancer: A scoping review

Critical Reviews in Oncology/Hematology(2022)10.1016/j.critrevonc.2022.103822

N/A

0.524DataRank · unranked

32 citations

Terri S. Armstrong, Joaquin A. Anguera, Kord M. Kober, Debra Lynch Kelly, Rob C. Laister +8 more

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.08.010

N/A

0DataRank · unranked

32 citations

John Kuruvilla, Julia Thornton Snider, Sachin Vadgama, Rob Blissett, Fadoua El Moustaid +4 more

CCTG LY18‐A phase I master protocol of novel combination therapy for patients with relapsed or refractory lymphoma ‐ the RGDP‐Venetoclax substudy

Hematological Oncology(2023)10.1002/hon.3164_441

N/A

0DataRank · unranked

1 citations

Diego Villa, Annette E. Hay, Nathalie A. Johnson, Michael Crump, Robert Kridel +10 more

142 | LISOCABTAGENE MARALEUCEL IN R/R FL (TRANSCEND FL): IMPACT OF PRIOR LINES OF THERAPY, BENDAMUSTINE EXPOSURE, AND DISEASE PROGRESSION ≤ 24 MONTHS OF INITIAL SYSTEMIC THERAPY

Hematological Oncology(2025)10.1002/hon.70093_142

N/A

0DataRank · unranked

0 citations

Juan Luis Reguera Ortega, Franck Morschhauser, Guillaume Cartron, Aaron P. Rapoport, Koji Izutsu +14 more